A01K 2267/035
Animal model for multifactorial diseases
A01K2267/035 (Animal model for multifactorial diseases) appears on 1,277 US grants and 2,374 published applications in this corpus.
Search patents in A01K- Granted patents
- 1,277
- Published applications
- 2,374
- Assignees
- 1,014
- Inventors
- 4,597
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 17 | 0 |
| 1997 | 21 | 0 |
| 1998 | 32 | 0 |
| 1999 | 36 | 0 |
| 2000 | 40 | 0 |
| 2001 | 36 | 13 |
| 2002 | 28 | 91 |
| 2003 | 47 | 129 |
| 2004 | 27 | 73 |
| 2005 | 25 | 96 |
| 2006 | 30 | 110 |
| 2007 | 35 | 91 |
| 2008 | 28 | 101 |
| 2009 | 32 | 96 |
| 2010 | 40 | 119 |
| 2011 | 48 | 110 |
| 2012 | 42 | 81 |
| 2013 | 50 | 70 |
| 2014 | 43 | 57 |
| 2015 | 68 | 108 |
| 2016 | 47 | 88 |
| 2017 | 57 | 79 |
| 2018 | 43 | 91 |
| 2019 | 52 | 98 |
| 2020 | 57 | 110 |
| 2021 | 64 | 102 |
| 2022 | 42 | 122 |
| 2023 | 39 | 116 |
| 2024 | 52 | 84 |
| 2025 | 54 | 84 |
| 2026 | 38 | 55 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A01K 2267/0362Animal model for lipid/glucose metabolismIndexing code287
- A01K 2267/0356Animal model for processes and diseases of the central nervous systemIndexing code247
- A01K 2267/0381Animal model for diseases of the hematopoietic systemIndexing code229
- A01K 2267/0375Animal model for cardiovascular diseasesIndexing code198
- A01K 2267/0387Animal model for diseases of the immune systemIndexing code192
- A01K 2267/0368Animal model for inflammationIndexing code157
Recent patents
- Non-human animals having humanized Fc-gamma receptors29 Sep 2026US 12,745,761 B2Regeneron Pharmaceuticals, Inc.
- Rat models for CMT2A that develop a progressive neuropathy1 Sep 2026US 12,721,327 B2Charcot-Marie-Tooth Association
- Fullerenes to treat diseases and conditions25 Aug 2026US 12,714,679 B2The Cleveland Clinic Foundation
- Methods and compositions for the expression of constitutively active RAP1A from a VMD2 promoter25 Aug 2026US 12,714,757 B2University of Flordia Research Foundation, Inc.
- KIR 7.1 gene therapy vectors and methods of using the same18 Aug 2026US 12,709,760 B2Wisconsin Alumni Research Foundation
- Transgenic model of human cardiomyopathy8 Oct 2026US 2026/0305586 A1Stichting Genetische Hartspierziekte PLN
- Cerebral microbleed animal model and preparation method therefor10 Sep 2026US 2026/0262614 A1Ajou University Industry-Academic Cooperation Foundation
- Methods and materials for treating gastrointestinal disorders27 Aug 2026US 2026/0248863 A1Mayo Foundation for Medical Education and Research
- Gene Editing to Improve Joint Function27 Aug 2026US 2026/0248955 A1Orthobio Therapeutics, Inc.
- Utilization of a hibernation-like state in neurological diseases27 Aug 2026US 2026/0248961 A1Okinawa Institute of Science and Technology School Corporation
Most cited
By later US patents
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,541US 5,661,016 AGenPharm International, Inc. · 1997
- Method of making transgenic mice lacking endogenous heavy chains1,057US 5,939,598 AAbgenix, Inc. · 1999
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Generation of xenogeneic antibodies639US 6,114,598 AAbgenix, Inc. · 2000
- Transgenic mice depleted in a mature lymphocytic cell-type491US 5,591,669 AGenPharm International, Inc. · 1997